Author

Damien A. Leach

Hammersmith HospitalORCID 0000-0003-3203-9826Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Charlotte Lynne BevaniD· 2 shared Alastair D.G. LambiD· 1 shared Alice Ormrod· 1 shared Anabel Varela‐Carver· 1 shared Aristotelis A. ChatziioannouiD· 1 shared Ash K. BahliD· 1 shared Chun‐Fui LaiiD· 1 shared Clémentine Le MagneniD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Charlotte Lynne BevanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 13, 2025

IRE1 activity regulates tumour and microenvironment cell lineage states while stratifying localised and metastatic prostate cancer.

Dimitrios Doultsinos, Ingrid Tomljanović, Eleftherios D. Pilalis…·Ian Geoffrey Mills

This paper identifies IRE1 activity as a regulator of prostate cancer cell lineage states and shows its role in predicting prognosis and treatment response across localized and metastatic disease.

DOI 10.1101/2025.03.13.643042

humanbulk RNA-seq

𝕏 PostBluesky

Molecular BiologyBritish Journal of CancerPeer-reviewedApr 19, 2023

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

Theodora A. Constantin, Anabel Varela‐Carver, Kyle K. Greenland…·Charlotte Lynne Bevan

This study investigates the antitumour activity of CT7001, a CDK7 inhibitor, in castration-resistant prostate cancer models, showing it inhibits proliferation and enhances enzalutamide efficacy.

29 citationstop 3%

humanexperimental assay

𝕏 PostBluesky